Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atipamezole SCHEMBL3626907 | 0.81 | ADRA2A (0.53) | SIRT2ENPP2 | |
| Formic Acid SCHEMBL7797545 | 0.71 | SIRT2 (0.37) | SIRT2CYP11B1CYP11B2ENPP2FLT3 | |
| SCHEMBL7269738 | 0.69 | SIRT2 (0.50) | SIRT2CYP11B1CYP11B2ENPP2FLT3 | |
| SCHEMBL7786406 | 0.69 | CYP11B1 (0.40) | MAPTRAB9ASMN1; SMN2SIRT2CYP11B1 | |
| SCHEMBL15487989 | 0.69 | CYP11B1 (0.40) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL7784539 | 0.69 | CYP11B1 (0.40) | MAPTRAB9ASMN1; SMN2SIRT2CYP11B1 | |
| SCHEMBL7787709 | 0.69 | CYP11B1 (0.37) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL7787713 | 0.69 | CYP11B1 (0.37) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL7786397 | 0.68 | CYP11B1 (0.39) | MAPTRAB9ASMN1; SMN2SIRT2CYP11B1 | |
| SCHEMBL8608329 | 0.68 | CYP11B1 (0.39) | MAPTRAB9ASMN1; SMN2SIRT2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431717-B2 | Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-yl)-1H-imidazole and salts thereof | JSC GRINDEKS (LV) | 2013-04-30 | — | — | US | claimed |
| EP-2225209-B1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | claimed |
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | JSC GRINDEKS (LV) | 2011-02-03 | — | — | US | claimed |
| EP-2225209-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | Grindeks, a joint stock company (LV) | 2010-09-08 | — | — | EP | claimed |
| WO-2009071584-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2009-06-11 | — | — | WO | claimed |
| US-8431717-B2 | Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-yl)-1H-imidazole and salts thereof | JSC GRINDEKS (LV) | 2013-04-30 | — | — | US | disclosed |
| US-8431717-B2 | Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-yl)-1H-imidazole and salts thereof | JSC GRINDEKS (LV) | 2013-04-30 | — | — | US | disclosed |
| US-8431717-B2 | Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-yl)-1H-imidazole and salts thereof | JSC GRINDEKS (LV) | 2013-04-30 | — | — | US | disclosed |
| EP-2225209-B1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | JSC GRINDEKS (LV) | 2011-02-03 | — | — | US | disclosed |
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | JSC GRINDEKS (LV) | 2011-02-03 | — | — | US | disclosed |
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | JSC GRINDEKS (LV) | 2011-02-03 | — | — | US | disclosed |
| EP-2225209-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | Grindeks, a joint stock company (LV) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009071584-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | CYP3A5, CYP3A4, IPO5 | GAA 824/4885MAPT 1241/4885RAB9A 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.